Trial · NCT03087578
Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder
NCT03087578, Not applicable, Withdrawn, University Hospitals Cleveland Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder. Trials, record NCT03087578. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03087578
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder
- NCT number
- NCT03087578
- Status
- Withdrawn
- Phases
- Not applicable
- Enrollment
- 0 participants, actual
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Conditions
- Overactive Bladder
- Interventions
- electroacupncture, Mirabegron 50 MG [Myrbetriq]
- First posted
- 2017-03-22
- Last updated
- 2022-05-06
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference in Incontinence Impact Questionnaire (IIQ-7) scores | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | change in IIQ-7 scores before and after initiation of treatment |
| Primary | Difference in Overactive Bladder Symptom Score (OABSS) | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | change in OABSS before and after initiation of treatment |
| Primary | Urogenital Distress Inventory (UDI-6) scores | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | change in UDI-6 scores before and after initiation of treatment |
| Primary | Differences in daytime frequency | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | before and after treatment |
| Primary | incontinence episodes | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | change in number of incontinence episodes before and after treatment |
| Primary | Nocturia | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | change in number of nocturia episodes before and after treatment |
| Secondary | Recurrence/worsening of symptoms | at baseline, 3 weeks after therapy initiation, 6 weeks after therapy initiation, and monthly intervals for 3 months from therapy initiation for the acupuncture group | Recurrence/worsening of symptoms after cessation of acupuncture treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36148895 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03087578
GET https://conductscience.org/api/trials/v1/NCT03087578/registered